SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp Nasdaq-100 selloff has traders focused on heavyweight tech earnings and concerns that soaring AI spending may not deliver returns fast enough, with some attributing added pressure to month-end liquidation and margin calls. The community is split between fears of a deeper AI-led correction and dip buyers looking for a rebound.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels weak fourth-quarter outlook, citing soft PC demand and manufacturing constraints, has driven a steep selloff, with analyst downgrades adding pressure. Traders are split between calling the drop an overreaction and buying the dip versus warning of further downside, while some see the move as part of a broader tech and semiconductor rout.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp, tech-led market selloff has put SPY in focus, with traders connecting the pressure to Amazon and Intel results and renewed concerns that heavy AI spending may not pay off. The discussion is largely bearish, with crash and liquidation fears competing against calls to buy the dip and expectations of a relief bounce.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is caught in a broader tech and semiconductor selloff as traders question whether hyperscalers heavy AI spending will deliver adequate returns; mixed Amazon and Intel results have added to concerns about AI infrastructure valuations. The community is divided between seeing an AI-bubble-driven reset and viewing the decline as a buying opportunity, with some arguing that continued capex still supports chip demand.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is under pressure amid a broad semiconductor and tech selloff, with traders repeatedly pointing to Intels weak outlook and softer PC demand as a drag on chip sentiment, alongside concerns about AI valuations. Its 3x leverage magnifies the downturn; the community is split between dip buyers anticipating a rebound and bears warning of further losses and leverage decay.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is selling off sharply despite a strong quarterly beat, upbeat guidance and an announced 8-for-1 split, as traders debate whether the drop reflects a broader tech and AI-stock unwind or concerns that memory pricing and earnings growth are nearing a cyclical peak. Many call the decline an overreaction and are buying the dip, while bears point to slowing growth and possible peak-cycle risks.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit shares plunged after its quarterly report paired strong results with a weaker-than-expected outlook, declining Google search referrals and signs of slowing user growth; plans to push users toward a logged-in experience added concern about traffic and ad reach. Traders are split between calling the selloff an overreaction given Reddits growth and profitability, and warning that search dependence and potential user losses threaten future growth.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is caught in a broad technology and semiconductor selloff as investors question AI spending returns and elevated chip valuations, with Intels weak outlook adding to sector pressure. Traders disagree over whether AMDs decline is justified or sympathy selling ahead of its earnings report, citing its data-center opportunity as a counterpoint.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff ahead of its earnings report is driving discussion, with traders pointing to analyst price-target cuts and concerns about ad-tech peers results and the broader market. Bulls argue the decline has made the companys valuation compelling, while bears fear weak results or guidance could bring further pressure.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 76,874.98691422 USD and is down -4.82 over the last 24 hours. It is currently trading on 12773 active market(s) with $58,826,736,014.03 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins selloff is being linked mainly to a reported major Binance security breach, with traders also citing leveraged liquidations and weakness in tech stocks as added pressure. The community is split between fears of further selling and exchange-related security risks, and dip-buyers arguing the incident affected Binance rather than Bitcoin itself and that the price has held up relatively well.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch 

Equity

Novo has 44 abstracts at EASD, including CagriSema analyses and Phase 2b Zenagamtide results.

SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment

SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment...

Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?

Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target...

Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS)

Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS...

Why Traders Are Piling into These Emerging Healthcare Names as New Catalysts Emerge

Biotechnology and healthcare innovation dominated investor conversations today as multiple companies delivered meaningful corporate, clinical, regulatory, and commercialization updates. From artificial intelligence-powered drug discovery platforms to neuro-oncology, regenerative medicine, wound care technologies, and autoimmune disease therapies, investors focused on companies that could potentially benefit from major industry trends while advancing important milestones of their own. $CUPR, $HYFT, $NTHI, $RGNT, $GELS, $SABS

MRNA, INO, SABS, NVAX Stocks Jump Premarket: Deadly Hantavirus Reaches US After Cruise Ship Outbreak 

The HHS confirmed that one American passenger evacuated from the MV Hondius cruise ship tested mildly positive for the Andes strain of hantavirus.

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Average Rating of "Moderate Buy" by Brokerages

SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, five have assigned a buy reco...

SAB Biotherapeutics (SABS) Expected to Announce Earnings on Friday

SAB Biotherapeutics (NASDAQ:SABS) will be releasing its Q1 2026 earnings before the market opens on Friday, May 8. (View Earnings Report at...

Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Expands By 19.8%

SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) saw a large increase in short interest in April. As of April 15th, there was short interest totaling 3,000,764 shares, an increase of 19.8...

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Average Rating of "Moderate Buy" from Analysts

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight analysts that are covering the firm, Marketbeat Ratings reports...

SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. It produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. The company was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL.

SAB Biotherapeutics Inc

Neutral Sentiment

<ul class="summary-bullets"><li>Lilly will present Phase 2 results for its eloraTZP combination at the EASD meeting in Milan.</li><li>SAB BIO, Sana and Century will present type 1 diabetes research at different stages of development.</li><li>uniQure expects a four-year AMT-130 update by quarter-end and Scynexis has guided to two Phase 1 updates.</li></ul><p>Biotech investors face a crowded final week of September as Eli Lilly (LLY) and Novo Nordisk (NVO) bring their latest obesity and diabetes research to a major medical meeting in Milan, while uniQure (QURE) and Scynexis (SCYX) approach quarter-end targets for clinical updates that could put smaller stocks in the spotlight.&nbsp;</p><p>The<a href="https://stocktwits.com/symbol/XLV">&nbsp;Health Care Select Sector SPDR Fund (XLV)</a> gained 1.8% last week, outperforming the broader market’s<a href="https://stocktwits.com/symbol/SPY">&nbsp;SPDR S&amp;P 500 ETF Trust (SPY)</a>, which rose 1.3%, but trailing the<a href="https://stocktwits.com/symbol/QQQ">&nbsp;Invesco QQQ Trust (QQQ)</a>, which climbed 3.3%. The<a href="https://stocktwits.com/symbol/IBB">&nbsp;iShares Biotechnology ETF (IBB)</a> advanced 2.6%, beating both <a class="mention" data-mention="$XLV" data-symbol-id="XLV" href="https://stocktwits.com/symbol/XLV" target="_blank">XLV</a> and SPY while lagging QQQ. The<a href="https://stocktwits.com/symbol/XBI">&nbsp;SPDR S&amp;P Biotech ETF (XBI)</a> fell 1.1%.&nbsp;</p><p><img src="https://news.stocktwits-cdn.com/healthcare_fef01ed028.png" alt="healthcare.png"></p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Date</td><td>Ticker/ Event</td><td>Development</td></tr><tr><td>Sept.28</td><td>CAMP</td><td>Camp4 Therapeutics holds an analyst day on its CMP-002 trial for SYNGAP1-related disorder.</td></tr><tr><td>Sept.28-Oct.2</td><td>EASD</td><td>Lilly, Novo and smaller biotech companies present diabetes and obesity research in Milan.</td></tr><tr><td>Sept.29</td><td>NVO, KURA</td><td>Novo presents CagriSema analyses, while Kura affiliate Caspian Therapeutics presents preclinical KO-7246 research.</td></tr><tr><td>Sept.30</td><td>LLY, NVO, SABS</td><td>Lilly presents Phase 2 eloraTZP results; Novo has several pipeline sessions; SAB BIO discusses SAB-142.</td></tr><tr><td>By Sept.30</td><td>QURE, SCYX</td><td>Potential four-year AMT-130 update from uniQure and two Phase 1 topline updates from Scynexis.</td></tr><tr><td>Oct.1</td><td>LLY, FDA</td><td>Lilly presents Foundayo data; an FDA panel discusses influenza vaccine strain selection.</td></tr><tr><td>Oct.2</td><td>SANA, IPSC</td><td>Sana and Century present separate type 1 diabetes cell-therapy programs.</td></tr></tbody></table></figure></div><h2 class="st-heading-2"><strong>Lilly, Novo Put Next Obesity Drugs On Display&nbsp;</strong></h2><p>The European Association for the Study of Diabetes’ annual meeting runs Monday through Friday in Milan, with obesity and diabetes presentations from Eli Lilly and Novo Nordisk. The program also includes type 1 diabetes research from SAB BIO (SABS), Sana Biotechnology (SANA) and Century Therapeutics (IPSC).<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.easd.org/annual-meeting/?utm_source=chatgpt.com">&nbsp;</a></p><p>On Wednesday, Lilly will present Phase 2 results for eloraTZP, a combination of the amylin-targeting drug Eloralintide and Tirzepatide, the ingredient in Mounjaro and Zepbound. The study involves adults with obesity or overweight and type 2 diabetes. Lilly will also discuss Phase 3 findings for Retatrutide, which targets three hormone receptors, and results from Surpass-CVOT, a study of Tirzepatide’s cardiovascular outcomes. Thursday’s session covers Phase 3 findings for its oral diabetes drug Foundayo, or Orforglipron. Lilly has already disclosed headline results from several of these studies and the presentations will add more details.</p><p>Novo has 44 abstracts at the meeting. Tuesday’s presentations include Reimagine 1 analyses of CagriSema’s effects on body composition and combined blood-sugar and weight-loss goals. On Wednesday, Novo will discuss CagriSema’s effects on appetite and responses to food cues, and present Phase 2b results for Zenagamtide, also known as Amycretin.</p><h2 class="st-heading-2"><strong>Smaller Biotechs Target Type 1 Diabetes&nbsp;</strong></h2><p>SAB BIO (SABS) will present research on SAB-142, an immunotherapy for type 1 diabetes, on Monday and Wednesday. Its Phase 1 findings address repeat dosing and early C-peptide signals. C-peptide helps show how much insulin a patient’s body still produces.</p><p>Friday features two cell-therapy programs at different stages. Sana Biotechnology (SANA) will discuss findings from a first-in-human study involving engineered donor insulin-producing cells transplanted into one patient without immunosuppressive drugs. Century Therapeutics (IPSC) will present preclinical research on manufacturing engineered stem-cell-derived insulin-producing cells for its CNTY-813 program.&nbsp;</p><p>Kura Oncology (KURA) is also linked to the diabetes program. Its separately financed affiliate, Caspian Therapeutics, will present Tuesday on KO-7246, an experimental drug being studied for its potential to increase insulin-producing beta cells.&nbsp;</p><h2 class="st-heading-2"><strong>Beyond Milan: 3 More Events To Watch This Week&nbsp;</strong></h2><p>Sellas Life Sciences (SLS) is also in focus as the AACR pancreatic-cancer conference concludes on Monday. The company released preclinical findings on its experimental drug SLS009 on Friday, ahead of three poster presentations&nbsp;that happened on Sunday. The studies examined SLS009 in pancreatic-cancer models, including combinations designed to address treatment resistance.</p><p>Camp4 Therapeutics (CAMP) has a confirmed event on Monday. Its analyst day will cover the design of a first-in-human Phase 1/2 trial of CMP-002 for Syngap1-related disorder. CAMP4 expects to start the trial in the fourth quarter.</p><p>Meanwhile, the FDA’s vaccine advisory committee is scheduled to meet on Thursday to recommend influenza virus strains for vaccines intended for the 2027 Southern Hemisphere season. Its recommendations are nonbinding.</p><h2 class="st-heading-2"><strong>Quarter-End Data Clock Ticks For QURE, SCYX&nbsp;</strong></h2><p>Outside the conference, uniQure (QURE) intends to present a four-year analysis of its AMT-130 gene-therapy studies in Huntington’s disease before the third quarter ends on Wednesday. The firm’s earlier guidance said the update would include four years of follow-up on 24 patients in its first two treatment cohorts.&nbsp;</p><p>uniQure submitted AMT-130 applications to U.S. and U.K. regulators earlier this month, supported by an earlier three-year analysis. The pending four-year update is a separate milestone. The company has requested priority review in the U.S.</p><p>Additionally, Scynexis (SCYX) has guided to two Phase 1 topline updates in the third quarter. Results for SCY-770, a potential treatment for inherited polycystic kidney disease, are expected to help select doses for a Phase 2 study. The other update concerns an intravenous version of SCY-247, an experimental antifungal.&nbsp;</p><h2 class="st-heading-2"><strong>Moderna’s Melanoma Details Remain Pending&nbsp;</strong></h2><p>Moderna (MRNA) and Merck (MRK) announced in August that their Phase 3 INTerpath-001 trial met its goals for delaying melanoma recurrence and the spread of cancer to distant parts of the body. The trial tested Moderna’s individualized cancer treatment Intismeran with Merck’s Keytruda after patients’ tumors had been surgically removed.&nbsp;</p><p>Investors are still awaiting the detailed results. The companies plan to present them at an “international medical meeting,” but have not named the conference or date.&nbsp;</p><h2 class="st-heading-2"><strong>LLY, NVO, QURE: How Do Retail Traders Feel?</strong></h2><p>Retail traders on Stocktwits turned more upbeat on LLY and QURE, even as chatter cooled. Sentiment on LLY improved to ‘neutral’ from ‘bearish’ over the past week, while message volume fell 10%. QURE sentiment rose to ‘bullish’ from ‘neutral’ a week ago, despite a 33% drop in 24-hour message volume.&nbsp;</p><p>NVO drew the most optimistic response: sentiment was ‘extremely bullish’ as message volume surged 100% over the past week.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/stla-f-gm-trump-fuel-economy-rollback-auto-plants-coming-back/cZMSWm8RBfh">STLA, F, GM Climb Overnight As Trump Clears Fuel Economy Rollback — Says Auto Plants Are ‘Coming Back’&nbsp;</a></p>

Representative Image (Photo credit: Getty Images)

Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch

iShares Biotechnology ETF

Century Therapeutics Inc

Lilly(Eli) & Co

Merck & Co Inc

Moderna Inc

Novo Nordisk A/S

uniQure NV

Sana Biotechnology Inc

Scynexis Inc

SELLAS Life Sciences Group Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.29
Prev Close	$3.23
Open	$3.18
Dividend Yield	0.00%
50-Day Moving Average	$3.27
Beta	0.74
Avg. Volume	584,387.22
PE Ratio	-1.95

52-Week High	$5.15
52-Week Low	$2.44
Market Capitalization	$293.89M
EPS (Annual)	-$0.7944
Price to Book	1.26
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

SABS Fundamentals